Scarica l'app Stockscreener
10.04
19.81%
1.66
Dopo l'orario di chiusura:
9.59
-0.45
-4.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Precedente Chiudi:
$8.38
Aprire:
$8.66
Volume 24 ore:
336.83K
Relative Volume:
10.32
Capitalizzazione di mercato:
$40.62M
Reddito:
$147.75M
Utile/perdita netta:
$-284.23M
Rapporto P/E:
-3.4266
EPS:
-2.93
Flusso di cassa netto:
$-317.54M
1 W Prestazione:
+20.10%
1M Prestazione:
+15.54%
6M Prestazione:
+52.18%
1 anno Prestazione:
+20.64%
Intervallo 1D:
$8.6001
$10.45
Intervallo di 1 settimana:
$8.37
$10.45
Portata 52W:
$4.85
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Nome
Fibrogen Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO, CA
Confronta FGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
10.04 | 33.90M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2020-05-01 | Iniziato | Cowen | Market Perform |
| 2020-04-27 | Iniziato | BofA/Merrill | Neutral |
| 2019-05-29 | Ripresa | Goldman | Neutral |
| 2019-05-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Iniziato | Piper Jaffray | Neutral |
| 2019-02-11 | Ripresa | Stifel | Buy |
| 2018-12-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2017-08-08 | Reiterato | Leerink Partners | Outperform |
| 2017-08-08 | Reiterato | Stifel | Buy |
| 2017-07-21 | Downgrade | Goldman | Buy → Neutral |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2016-02-11 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
| 2015-12-04 | Iniziato | Citigroup | Buy |
| 2015-09-23 | Iniziato | Lake Street | Hold |
| 2015-07-29 | Iniziato | Citigroup | Buy |
| 2015-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2014-12-09 | Iniziato | Stifel | Buy |
Mostra tutto
Fibrogen Inc Borsa (FGEN) Ultime notizie
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen shares advance after roxadustat earns orphan drug status - MSN
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission - Quiver Quantitative
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
Market Review: Will FibroGen Inc stock keep outperforming rivals2025 Risk Factors & Breakout Confirmation Trade Signals - moha.gov.vn
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
FibroGen, Inc. to Present at Oppenheimer Movers in Rare Disease Summit on December 11, 2025 - Quiver Quantitative
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
Will FibroGen Inc. stock outperform international peers2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Why FibroGen Inc. (1FG0) stock is trending on social mediaJuly 2025 PreEarnings & AI Enhanced Execution Alerts - moha.gov.vn
FibroGen started at buy by H.C. Wainwright - MSN
What valuation multiples suggest for FibroGen Inc. stockWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Can FibroGen Inc. (1FG0) stock ride next bull market cycle2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Why FibroGen Inc. stock remains resilientPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Can FibroGen Inc. (1FG0) stock deliver consistent EPS growthJuly 2025 Decliners & Weekly Top Gainers Alerts - newser.com
Is FibroGen Inc. stock vulnerable to regulatory risks2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Can FibroGen Inc. (1FG0) stock resist broad market declines2025 Volatility Report & Intraday High Probability Alerts - newser.com
Will earnings trigger a reversal in FibroGen Inc.Trade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
What drives FibroGen Inc stock priceCandlestick Trading Patterns & Free Take Advantage Of Momentum - earlytimes.in
Chart based exit strategy for FibroGen Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
What hedge fund activity signals for FibroGen Inc. stockWeekly Trading Summary & Daily Growth Stock Investment Tips - newser.com
Fibrogen Inc Azioni (FGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):